Optimizing the use of outcome measures in chronic inflammatory demyelinating polyneuropathy

Jeffrey A. Allen, Deborah F. Gelinas, Richard A. Lewis, Richard J. Nowak, Gil I. Wolfe

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


The challenges encountered during the assessment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) are many. Ideally, CIDP outcome measures capture impairments in disability, strength, and sensory dysfunction, and quality of life (QoL). A number of outcome measures have been validated for this purpose. Disability outcomes include the adjusted inflammatory neuropathy cause and treatment (INCAT) disability score, INCAT overall disability sum score (ODSS), and overall neuropathy limitations scale (ONLS). A more sensitive disability score, the inflammatory Rasch-built overall disability scale (I-RODS), has also been validated for use in clinical trials and may better capture clinically meaningful changes in those with CIDP. Strength and sensory impairment can be assessed in a number of ways, including the INCAT sensory subscore (ISS), Medical Research Council sum score, and Martin vigorimeter or Jamar dynamometer grip strength. However, the feasibility of applying and interpreting these measures during routine daily practice has been questioned. Furthermore, these outcome measures may not reflect other factors that can impair QoL in those affected by CIDP, such as pain and fatigue. A valid, reliable, and responsive composite measure that addresses all aspects of impairment faced by patients with CIDP remains an unmet need in clinical practice.

Original languageEnglish (US)
Pages (from-to)26-33
Number of pages8
JournalEuropean Neurological Review
Issue number1
StatePublished - 2017

Bibliographical note

Publisher Copyright:
© 2017, Touch Briefings. All Rights Reserved.


  • Chronic inflammatory demyelinating polyneuropathy
  • Disability
  • Grip strength
  • Impairment
  • Outcome measures


Dive into the research topics of 'Optimizing the use of outcome measures in chronic inflammatory demyelinating polyneuropathy'. Together they form a unique fingerprint.

Cite this